Mylan is one of the world’s leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world’s largest active pharmaceutical ingredient (API) manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced.

**Our Mission**

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what’s right, not what’s easy
- Impact the future through passionate global leadership

Creating better health for a better world. That’s what inspires Mylan in our mission to provide quality healthcare to the world’s 7 billion people, one person at a time.

---

**Fast Facts**

**Global workforce:** nearly 35,000

**Products:** a global market portfolio of more than 1,400 separate products

**Product submissions:** more than 4,100 new product submissions pending regulatory approval around the world

**Global presence:** sell products in approximately 165 countries and territories

**U.S. presence:** one out of every 13 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product

**Manufacturing presence:** operate more than 40 facilities around the globe

**Manufacturing capacity:** a total capacity of 65 billion oral solid doses, 3,600 kiloliters of APIs, 500 million injectable units, 260 million patches and 15 million semisolid units

**R&D capabilities:** include an extensive range of dosage forms and delivery systems, including oral solid doses, transdermal patches, injectables, respiratory inhalants, topicals, soft gel capsules, nasal sprays, solutions, suspensions, ophthalmics, ARVs and APIs

**ARV access:** nearly 50% of people living with HIV/AIDS in the developing world who are receiving treatment depend on a Mylan product

**Notable:** member of S&P 500
Our Evolution

1961
Founded by Milan “Mike” Puskar and Don Panoz in White Sulphur Springs, West Virginia, U.S.

1973
Became a publicly traded company

1984
Received our first branded product approval

2002
Generated more than $1 billion in revenue for the first time

2007
Went global with the acquisitions of Matrix and Merck Generics

2012
Helped champion the U.S. Food and Drug Administration Safety and Innovation Act

2013
Acquired Agila Specialties and became a global injectables leader

2015
Acquired Abbott’s non-U.S. developed markets specialty and branded generics business
Acquired certain businesses from Famy Care to become a global women’s care leader

Powerful Global Commercial Presence

U.S.
One in 13 prescriptions in the U.S., brand name or generic, is filled with a Mylan product

India
Mylan is India’s third largest pharmaceuticals exporter for fiscal year 2014

Canada
Mylan products are sold in eight out of 10 pharmacies in Canada

Europe
Mylan holds leadership positions in several key European markets, including France, Italy, the Netherlands, Portugal and the U.K.

Japan
Fastest grower in the Japan generics market in the last three years*

Australia
Mylan is the No. 1 supplier by volume to Australia’s national pharmaceuticals program

*Excluding authorized generics

Executive Management Team

Robert J. Coury
Executive Chairman

Heather Bresch
Chief Executive Officer

Rajiv Malik
President

Tony Mauro
Chief Commercial Officer

Media Relations:
+1.724.514.1968
communications@mylan.com

Investor Relations:
+1.724.514.1813
investor.relations@mylan.com

Stay Connected

©2016 Mylan N.V. All rights reserved. (April 2016)
The Mylan logo is a registered trademark of Mylan Inc.